Expanded Access Program to Make Niraparib Available to More U.S. Ovarian-cancer Patients
News
Women with epithelial-ovarian, fallopian-tube, or primary-peritoneal cancer who are not eligible for niraparib clinical trials, and who lack alternative therapies, may obtain the treatment under the expanded access program (EAP) ... Read more